RU2007148504A - Индановые производные в качестве модуляторов ионных каналов - Google Patents
Индановые производные в качестве модуляторов ионных каналов Download PDFInfo
- Publication number
- RU2007148504A RU2007148504A RU2007148504/04A RU2007148504A RU2007148504A RU 2007148504 A RU2007148504 A RU 2007148504A RU 2007148504/04 A RU2007148504/04 A RU 2007148504/04A RU 2007148504 A RU2007148504 A RU 2007148504A RU 2007148504 A RU2007148504 A RU 2007148504A
- Authority
- RU
- Russia
- Prior art keywords
- group
- compound
- compound according
- optionally
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 58
- -1 1,2-methylenedioxy Chemical group 0.000 claims abstract 30
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 24
- 229910052736 halogen Inorganic materials 0.000 claims abstract 21
- 150000002367 halogens Chemical class 0.000 claims abstract 21
- 125000001424 substituent group Chemical group 0.000 claims abstract 19
- 239000000126 substance Substances 0.000 claims abstract 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 14
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 14
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 11
- 125000005842 heteroatom Chemical group 0.000 claims abstract 9
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 125000003118 aryl group Chemical group 0.000 claims abstract 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 5
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 4
- 125000006413 ring segment Chemical group 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 238000000034 method Methods 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 208000008930 Low Back Pain Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 206010059604 Radicular pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000001788 irregular Effects 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 1
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68891905P | 2005-06-09 | 2005-06-09 | |
| US60/688,919 | 2005-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007148504A true RU2007148504A (ru) | 2009-06-27 |
Family
ID=37000013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007148504/04A RU2007148504A (ru) | 2005-06-09 | 2006-06-09 | Индановые производные в качестве модуляторов ионных каналов |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7605174B2 (enExample) |
| EP (1) | EP1888547A1 (enExample) |
| JP (2) | JP2008543785A (enExample) |
| KR (1) | KR20080019693A (enExample) |
| CN (1) | CN101238109B (enExample) |
| AU (1) | AU2006254809B2 (enExample) |
| CA (1) | CA2611731A1 (enExample) |
| IL (1) | IL187997A0 (enExample) |
| MX (1) | MX2007015726A (enExample) |
| NO (1) | NO20080141L (enExample) |
| NZ (1) | NZ564374A (enExample) |
| RU (1) | RU2007148504A (enExample) |
| WO (1) | WO2006133459A1 (enExample) |
| ZA (1) | ZA200800191B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| MX2007014180A (es) * | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
| EP1888558B1 (en) * | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| MX2008003337A (es) * | 2005-09-09 | 2008-09-26 | Vertex Pharma | Derivados biciclicos como modulares de canales ionicos regulados por voltaje. |
| CA2624329A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals |
| CN101331115A (zh) * | 2005-10-21 | 2008-12-24 | 沃泰克斯药物股份有限公司 | 调控离子通道的衍生物 |
| RU2008129821A (ru) | 2005-12-21 | 2010-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| EP2158183A2 (en) | 2007-05-25 | 2010-03-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| NZ585332A (en) * | 2007-11-13 | 2012-05-25 | Vertex Pharma | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain |
| ES2377172T3 (es) * | 2007-11-13 | 2012-03-23 | Vertex Pharmaceuticals Incorporated | Derivados heterocíclicos como moduladores de canales iónicos |
| CN101978787A (zh) * | 2008-04-30 | 2011-02-16 | 夏普株式会社 | 照明装置和显示装置 |
| US7846954B2 (en) * | 2008-07-01 | 2010-12-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CA2732757A1 (en) * | 2008-08-06 | 2010-02-11 | Merck Sharp & Dohme Corp. | Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers |
| MX2014005068A (es) * | 2011-10-28 | 2014-07-30 | Merck Sharp & Dohme | Compuestos de benzoxazolinona con actividad selectiva en canales de sodio activados por voltaje. |
| ES2798138T3 (es) | 2012-10-15 | 2020-12-09 | Dae Woong Pharma | Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos |
| IL269964B1 (en) | 2013-01-31 | 2025-09-01 | Vertex Pharma | Pyridone amide compounds, compositions containing them and uses thereof |
| CA3024989C (en) | 2016-05-19 | 2024-02-27 | Tabula Rasa Healthcare, Inc. | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications |
| EP3820860B1 (en) | 2018-07-09 | 2025-10-15 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting nav1.8 |
| WO2020014246A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| WO2020169042A1 (zh) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| PE20250155A1 (es) | 2021-06-14 | 2025-01-22 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cancer |
| CN116041230B (zh) * | 2023-01-08 | 2024-03-19 | 中国海洋大学 | 一种nlrp3炎症小体抑制剂及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9800750D0 (en) * | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| NZ579370A (en) | 2003-08-08 | 2011-06-30 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
-
2006
- 2006-06-09 KR KR1020087000464A patent/KR20080019693A/ko not_active Withdrawn
- 2006-06-09 EP EP06772925A patent/EP1888547A1/en not_active Withdrawn
- 2006-06-09 CN CN2006800287819A patent/CN101238109B/zh not_active Expired - Fee Related
- 2006-06-09 US US11/450,695 patent/US7605174B2/en active Active
- 2006-06-09 ZA ZA200800191A patent/ZA200800191B/xx unknown
- 2006-06-09 NZ NZ564374A patent/NZ564374A/en not_active IP Right Cessation
- 2006-06-09 JP JP2008516024A patent/JP2008543785A/ja not_active Ceased
- 2006-06-09 WO PCT/US2006/022818 patent/WO2006133459A1/en not_active Ceased
- 2006-06-09 AU AU2006254809A patent/AU2006254809B2/en not_active Ceased
- 2006-06-09 MX MX2007015726A patent/MX2007015726A/es active IP Right Grant
- 2006-06-09 RU RU2007148504/04A patent/RU2007148504A/ru not_active Application Discontinuation
- 2006-06-09 CA CA002611731A patent/CA2611731A1/en not_active Abandoned
-
2007
- 2007-12-09 IL IL187997A patent/IL187997A0/en unknown
-
2008
- 2008-01-09 NO NO20080141A patent/NO20080141L/no not_active Application Discontinuation
-
2009
- 2009-08-31 US US12/550,649 patent/US7989481B2/en active Active
-
2012
- 2012-03-29 JP JP2012076707A patent/JP2012126745A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NO20080141L (no) | 2008-01-09 |
| WO2006133459A1 (en) | 2006-12-14 |
| US7989481B2 (en) | 2011-08-02 |
| NZ564374A (en) | 2010-11-26 |
| MX2007015726A (es) | 2008-03-04 |
| JP2012126745A (ja) | 2012-07-05 |
| CA2611731A1 (en) | 2006-12-14 |
| ZA200800191B (en) | 2009-04-29 |
| CN101238109A (zh) | 2008-08-06 |
| US20070117801A1 (en) | 2007-05-24 |
| AU2006254809A1 (en) | 2006-12-14 |
| KR20080019693A (ko) | 2008-03-04 |
| HK1119433A1 (en) | 2009-03-06 |
| CN101238109B (zh) | 2011-12-14 |
| AU2006254809B2 (en) | 2012-03-15 |
| US20090326023A1 (en) | 2009-12-31 |
| JP2008543785A (ja) | 2008-12-04 |
| IL187997A0 (en) | 2008-03-20 |
| US7605174B2 (en) | 2009-10-20 |
| EP1888547A1 (en) | 2008-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
| RU2007145434A (ru) | Бициклические производные в качестве модуляторов ионных каналов | |
| KR102562866B1 (ko) | 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체 | |
| CN112601750B (zh) | Ptpn11（shp2）抑制剂 | |
| CA3088927C (en) | Biaryl derivative, preparation method therefor and pharmaceutical use thereof | |
| CA3122317C (en) | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound | |
| RU2007146769A (ru) | Бициклические производные и их применение в качестве модуляторов ионых каналов | |
| KR102534262B1 (ko) | 헤테로환형 유도체 및 이의 용도 | |
| US20070060595A1 (en) | Novel fused heterocyclic compound and use thereof | |
| JP5615902B2 (ja) | イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体 | |
| RU2008113836A (ru) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов | |
| JP2018515492A5 (enExample) | ||
| JP2008540661A5 (enExample) | ||
| CA2616451C (en) | Substituted benzyl derivatives as gsk-3 inhibitors | |
| RU2008118350A (ru) | Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов | |
| JP2008543785A5 (enExample) | ||
| JP2009511599A5 (enExample) | ||
| KR20160115996A (ko) | 피라졸론 화합물 및 이의 용도 | |
| JP6619796B2 (ja) | Ｍｉｆ阻害剤 | |
| WO2016117647A1 (ja) | 新規ベンズイミダゾール誘導体およびその医薬用途 | |
| JP2015502371A5 (enExample) | ||
| RU2621708C2 (ru) | Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| RU2011108485A (ru) | Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств | |
| MX2009002905A (es) | Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100719 |